Introduction
Chronic myeloid leukemia (CML) is characterized by the BCR-ABL fusion gene, which is formed in 95% of patients through a chromosomal rearrangement that creates the Philadelphia chromosome.
1 BCR-ABL encodes an oncogenic tyrosine kinase, whose activity in hematopoietic stem cells leads to the development of CML in chronic phase (CP). 2 Studies into the molecular basis of CML have led to the development of targeted therapies that block the kinase activity of BCR-ABL. In patients, receiving treatment for CML, qualitative and quantitative assessment of BCR-ABL transcripts by real-time-polymerase chain reaction (RTFPCR) is the most sensitive method for measuring minimal residual disease. 3 Dasatinib (SPRYCEL, Bristol-Myers Squibb, New York, NY, USA) is a highly potent tyrosine kinase inhibitor of BCR-ABL that is 325-fold more potent than imatinib (Glivec/Gleevec, Novartis, Basel, Switzerland) against unmutated BCR-ABL in vitro. 4 Across a series of phase II and III trials with more than 24 months of follow-up, dasatinib has shown durable efficacy in patients with CML after resistance, suboptimal response, or intolerance to prior imatinib. [5] [6] [7] [8] [9] After a phase III dose optimization study showing comparable efficacy and significantly lower rates of key side effects with dasatinib 100 mg once daily (QD) compared with 70 mg twice daily (BID), 7 dasatinib 100 mg QD is now the approved dose in CML-CP.
Dasatinib treatment of patients with CML-CP after failure of prior imatinib results in high rates of major molecular response (MMR). In the START-C trial, the overall MMR rate after 24 months of follow-up was 45%, and 78% of patients who achieved complete cytogenetic response (CCyR) also achieved an MMR. 10 In the START-R trial of patients with resistance to imatinib 400-600 mg/day, patients in the dasatinib arm achieved a significantly higher MMR rate than patients randomized to imatinib 800 mg/day (29 vs 12%; P ¼ 0.028).
11
During imatinib treatment of CML in the first-line setting, achievement of an MMR is associated with a very low probability of disease progression. 12, 13 Furthermore, in independent studies of patients who received imatinib either immediately after diagnosis or after failure of prior interferonalpha, achieving an MMR was associated with significantly longer duration of cytogenetic remission and progressionfree survival (PFS). [14] [15] [16] [17] [18] [19] [20] To date, no studies of secondline tyrosine kinase inhibitor treatment for CML have been published that analyze BCR-ABL molecular response dynamics or the importance of MMR for predicting longterm outcomes. In the current analysis, the dynamics and predictive value of a MMR during dasatinib treatment were investigated in patients with CML-CP who were recruited to phase II/III trials.
Methods

Patients and treatment
Patient data were analyzed from three dasatinib trials in CML-CP: CA180-013, À017, and À034. Study 013 (START-C) is a phase II trial of dasatinib 70 mg BID in 387 patients with resistance (n ¼ 288) or intolerance (n ¼ 99) to imatinib. 5, 21 Study 017 (START-R) is a phase II randomized trial of dasatinib 70 mg BID vs imatinib 800 mg/day in patients with resistance to imatinib 400-600 mg/day, including 101 patients who were randomized to dasatinib. 6 Study 034 is a phase III doseoptimization trial in patients with resistance, suboptimal response, or intolerance to imatinib (n ¼ 670), in which patients were randomized using a 2 Â 2 factorial design to receive one of four dosing schedules: 100 mg QD (n ¼ 167), 50 mg BID (n ¼ 168), 140 mg QD (n ¼ 167), or 70 mg BID (n ¼ 168). 7 In all the three studies, dasatinib dose escalation (to a maximum of 180 mg QD or 90 mg BID) was permitted for inadequate response and dose interruption or reduction (to a minimum of 80 mg QD or 40 mg BID) was permitted for adverse events. Trials were conducted in accordance with the Declaration of Helsinki and were approved by the Institutional Review Board/ Ethics Committee at each participating center. Written informed consent was obtained from all patients.
Assessments
Patient samples were assayed at one of four laboratories: the University of Heidelberg, Mannheim, Germany; Institute of Medical and Veterinary Science, Adelaide, Australia; or Fred Hutchinson Cancer Research Center, Seattle, WA, USA (Studies 013 and 017) and the Bristol-Myers Squibb (BMS) laboratory in Hopewell, NJ, USA (Study 034). At baseline and every 3 months after dasatinib therapy, peripheral blood samples (10 ml in Studies 013 and 017, 2.5 ml in Study 034) were collected into PAXgene Blood RNA Tubes (PreAnalytiX Hombrechtikon, Switzerland), stored for 2 h at room temperature, and then frozen at -20 1C. RNA was extracted from total blood according to the manufacturer's instructions and reverse transcribed. The BCR-ABL transcript level was quantified from cDNA by RT-PCR (nested PCR in Studies 013 and 017) using standardized protocols and TaqMan or Lightcycler technologies. 13, [22] [23] [24] Levels were expressed as a percentage ratio of total BCR-ABL (b3a2 and b2a2) to BCR, ABL, or b-glucuronidase (GUSB) transcripts, which were converted to the international scale using lab-specific conversion factors. 13, 25 On the basis of assay parameters, the PCR assay performed at the BMS laboratory (Study 034) was less sensitive than in other laboratories. Mutation analysis of the BCR-ABL kinase domain was performed at baseline by RT-PCR and direct sequencing, with or without denaturing high-performance liquid chromatography. 26, 27 MMR was defined as a reduction in the ratio of BCR-ABL:control gene transcripts to p0.1% of the standardized baseline. 3 During each trial, patients were also assessed using conventional metaphase karyotype analysis to determine cytogenetic responses, as described earlier. 21 
Analyses
Time to MMR was analyzed using a Kaplan-Meier technique in which all nonresponders were censored at the same maximum assessment time. The resulting curve represents the MMR rate over the observed period and reaches a maximal value corresponding to the overall observed MMR rate. Standard Kaplan-Meier methodology was used for landmark analysis of duration of CCyR, PFS and overall survival (OS), and 95% confidence intervals (CI) were calculated. Patients who had a duration of CCyR, PFS, or OS less than the landmark, or those who did not have responses assessed within the landmark window ( ± 1.5 months) were not included in the analysis.
All P-values were calculated for descriptive purposes only using the log-rank test; statistical significance could not be judged as no adjustment for multiple comparisons was performed. As a sensitivity analysis, stratified log-rank tests were performed with stratification by study to take into account possible heterogeneity between the different clinical studies.
Progression was defined as confirmed accelerated-phase or blast-phase disease, loss of an earlier complete hematologic response or major cytogenetic response , increase in Ph þ metaphases of 30% or more (Study 034 only), increasing white blood cell count (doubling from lowest value to more than 20 000/mm 3 or an increase of more than 50 000/mm 3 on two occasions, performed at least 2 weeks apart), or death. Duration of CCyR was defined as time from achievement of CCyR until either loss of CCyR (unconfirmed) or progression. Patients who did not progress/lose response were censored at last assessment. Patients were not followed for PFS/duration of CCyR analysis after study drug discontinuation for protocol-stipulated reasons, which included withdrawal of informed consent; any adverse event, laboratory abnormality, or intercurrent illness that in the investigator's opinion, indicated that continued treatment was not in the patient's best interest; pregnancy; and stem-cell transplant (034 study). For OS analysis, patients who did not die or were lost to follow-up were censored on last known alive date. In study 034, patients were followed for survival status regardless of whether or not they discontinued study drug. In START-R, OS was not assessed because of the crossover design of the study.
Results
Patient characteristics
A total of 1158 patients with CML-CP after imatinib failure were randomized to (Studies 017 and 034) or treated with (Study 013) dasatinib. Of these, 1067 underwent molecular assessment during dasatinib treatment and were included in the current analysis (Table 1) . In all three studies, minimum follow-up was 24 months (last patient first visit to database lock). Consistent with earlier reports, patients recruited to dasatinib trials after resistance/suboptimal response to imatinib had a longer median duration of CML and prior imatinib treatment, and a higher rate of baseline BCR-ABL mutations, than patients recruited after imatinib intolerance.
Major molecular responses during dasatinib treatment
After 3, 6, 12, and 24 months of follow-up, cumulative rates of MMR in the total analysis group were 12, 22, 35, and 40%, respectively ( Figure 1a ). In patients with resistance or suboptimal response to imatinib (n ¼ 829), MMR rates after 3, 6, 12, and 24 months were 10, 18, 29, and 34%, respectively, whereas in patients with intolerance to imatinib (n ¼ 238), rates were 22, 37, 55, and 63%, respectively. MMR rates from the phase II/III studies are shown in Table 2 . Among patients who achieved an MMR, the median time to MMR was 5.7 months (95% CI 5.6-5.9) in the total group, 5.8 months (5.6-6.4) in patients with resistance/suboptimal response to imatinib, and 5.6 months (5.5-5.8) in intolerant patients. Time to MMR with dasatinib 100 mg QD was similar to other dose schedules, including 70 mg BID (Figure 1b) . Among patients who achieved a CCyR, the 24-month MMR rate was 72% (67% in resistant patients/suboptimal responders, 83% in intolerant patients). In patients with resistance or suboptimal response to imatinib in whom mutational assessment had been performed, MMR rates in patients with (n ¼ 367) or without (n ¼ 404) a BCR-ABL mutation at baseline were 31and 36%, respectively.
BCR-ABL transcript reductions to p1% during dasatinib treatment
To investigate molecular responses other than MMR, time to BCR-ABL transcript reduction to p1% (i.e. 10-fold higher level of transcripts than an MMR) was examined. After 3, 6, 12, and 24 months of follow-up, a BCR-ABL transcript level reduction to p1% had been achieved by 30, 41, 51, and 55% of patients, respectively (Figure 2 ). Among patients who had achieved a BCR-ABL level p1%, median time to response was 2.8 months (95% CI 2.8-3.0) in the total group, 3.0 months (2.8-5.4) in resistant patients/suboptimal responders and 2.8 months (2.5-2.8) in intolerant patients.
Long-term outcomes according to molecular response achieved with dasatinib
In landmark analyses, PFS and OS were assessed according to achievement of MMR after 12 months of dasatinib treatment (Figure 3) . The 12-month landmark was selected because a reasonable proportion of patients had achieved MMR and the period of subsequent follow-up enabled reasonable analysis of PFS or OS. In patients who did or did not achieve an MMR at 12 months, 24-month PFS rates were 96 vs 82%, respectively (Po0.0001) and 24-month OS rates were 98 vs 97% (P ¼ 0.095).
PFS and OS were further analyzed according to the achievement at 12 months of MMR, CCyR only (no MMR), or no CCyR/no MMR (Figure 4) . Patients with no MMR who had no cytogenetic assessment within the landmark window, and patients with Ph-negative BCR-ABL-positive disease, were excluded. PFS rates at 24 months were 96% in patients who achieved MMR, 97% in patients who achieved CCyR only (P ¼ 0.53 vs patients who achieved MMR), and 78% in patients who achieved no CCyR/no MMR (Po0.0001 vs patients who achieved MMR). Corresponding OS rates at 24 months were 98%, 100% (P ¼ 0.63), and 96% (P ¼ 0.033). To confirm that patients not included in the analyses because of no cytogenetic assessment within the landmark window did not affect the overall trend of the curves, sensitivity analyses were performed (i.e. considering excluded patients in the CCyR or no CCyR group; data not shown).
Data were further analyzed to determine whether achieving an MMR at 12 months influenced duration of the CCyR. Among patients who were in CCyR and underwent molecular assessment within the landmark window, 86% of patients who achieved MMR at 12 months remained in CCyR at 24 months, (17) 62 (26) Dasatinib dose received, n (%) 100 mg QD 153 (14) 116 (14) 37 (16) CCyR, complete cytogenetic response; CHR, complete hematologic response; CML, chronic myeloid leukemia; MCyR, major cytogenetic response.
Dasatinib-associated major molecular responses in patients with CML A Hochhaus et al compared with 64% of those who did not achieve MMR ( Figure 5 , P ¼ 0.0006). For all landmark analyses, when controlling for possible heterogeneity between clinical studies (013, 017, and 034) using a stratified test, similar findings were observed in each case except for the analysis of OS according to MMR, CCyR only (no MMR), or no CCyR/no MMR at 12 months. In the stratified test of this landmark analysis, no evidence of difference between the groups was found, most likely reflecting the small number of deaths within available follow-up.
Discussion
The results of this pooled analysis, comprising three trials with more than 24 months of follow-up and more than 1000 patients, show that dasatinib treatment results in high rates of MMR in patients with CML-CP after imatinib failure. The total cumulative MMR rate was 40%, including 34% of patients with resistance or suboptimal response to imatinib and 63% of patients with intolerance to imatinib. MMRs were achieved rapidly, with a median time to MMR in responding patients of less than 6 months. Time to MMR with dasatinib 100 mg QD, the current approved dose in CML-CP, was similar to other doses including dasatinib 70 mg BID.
Despite the extensive pretreatment of patients analyzed, including a high proportion who had received interferon-alpha Figure 2 Rates of BCR-ABL transcript reduction to p1% during dasatinib treatment of patients with prior imatinib failure. Dasatinib-associated major molecular responses in patients with CML A Hochhaus et al in addition to imatinib, MMR rates achieved with dasatinib seem to compare favorably to those achieved with imatinib in newly diagnosed patients with CML-CP. In the IRIS trial (International Randomized study of Interferon versus ST1571), the estimated MMR rates after 6 and 12 months of primary imatinib treatment were 21 and 39%, respectively. 13 In this analysis, 6-and 12-month MMR rates in the total group were 22 and 35%, and in imatinib-intolerant patients, rates were 37 and 55%, respectively. However, any comparison in response rates between studies should be interpreted with caution because of the differences in study designs and patient populations.
Earlier analyses, including those from the IRIS trial, have reported that achieving a timely MMR or CCyR during first-line imatinib treatment is predictive for subsequent outcome. [12] [13] [14] 28 Among IRIS patients who achieved an MMR within 12 months, 100% were free from disease progression and loss of complete hematologic response or major cytogenetic response at 24 months, compared with 95% who achieved a CCyR but no MMR (P ¼ 0.007), and 85% who achieved no CCyR (P ¼ 0.013). 11 In addition, 100% of patients with an MMR at 18 months remained free from transformation to acceleratedphase or blast-phase CML at 60 months, compared with 98% of those who achieved a CCyR but no MMR (P ¼ 0.11), and 87% who achieved no CCyR (Po0.001). 12 The results of the landmark analyses presented here show that in patients treated with dasatinib after imatinib failure, MMR or CCyR achieved within 12 months of dasatinib treatment is predictive for favorable outcome. In dasatinib-treated patients who had achieved or maintained an MMR at 12 months, the 24-month PFS rate was higher than in patients who did not achieve a 12-month MMR, although OS was similar. However, when data were analyzed further, patients who achieved a CCyR but no MMR had similar rates of PFS and OS to those who achieved MMR, whereas patients who did not achieve a CCyR (or MMR) had lower rates of PFS and OS. These data suggest that similar to first-line treatment with imatinib, achievement of a CCyR with dasatinib after imatinib failure may be associated with the greatest predictive benefit for long-term outcomes, with a smaller incremental benefit for achieving a MMR. It should be noted that PFS rates were still relatively high among patients who had not yet achieved MMR or CCyR after 12 months of dasatinib treatment, with more than 75% remaining free from loss of complete hematologic response/major cytogenetic response or progression to accelerated-phase/blast-phase at 24 months. In a recent analysis of first-line imatinib treatment for CML-CP, patients who achieved an MMR at 12 months had a similar PFS and OS to those who achieved CCyR without MMR at 12 months, but were less likely to experience loss of CCyR. 14 Other studies, including patients with late CML-CP, have also reported an association between MMR and extended duration of CCyR. [16] [17] [18] [19] In the present analysis, achievement of an MMR at 12 months during dasatinib treatment was also associated with a longer duration of CCyR. This may suggest that achieving an MMR provides a similar additional benefit over CCyR alone during both first-line imatinib treatment and during dasatinib treatment after imatinib failure. However, the relative importance of different response milestones during dasatinib treatment requires further investigation, and future analyses will be performed to examine other time points for response, levels of response, and characteristics of responding patients.
In conclusion, this analysis shows that dasatinib induces rapid MMRs in a high proportion of patients with CML-CP after resistance, suboptimal response, or intolerance to imatinib. Progression-free survival is most favorable in patients who have achieved MMR or CCyR within 12 months, although PFS rates remain high in dasatinib-treated patients who do not achieve a 12-month MMR or CCyR.
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